Restrictive allograft dysfunction after lung transplantation: is there a place for nintedanib?-a case report.

Hélène Pluchart, Sébastien Chanoine, Amandine Briault, Johanna Claustre, Pierrick Bedouch

Fundamental & clinical pharmacology 2020 Jun

filter terms:

One of the posttransplantation complications is represented by chronic lung allograft dysfunction, which has two main clinical presentations: bronchiolitis obliterans syndrome and restrictive allograft syndrome. The latter being challenging because of poor prognosis and only symptomatic treatment, and characterized by fibrotic process. A 63-year-old man was right lung-transplanted in 2009 due to idiopathic pulmonary fibrosis. In 2011, bronchiolitis obliterans syndrome was diagnosed evolving to restrictive allograft syndrome in 2016. An off-label treatment by nintedanib (150 mg twice a day) was introduced. Unfortunately, it was stopped 4 months later because of digestive intolerance, without any clinical improvement. Contrary to a previous case reported, our patient did not have any benefit of nintedanib. Antifibrotic agents' effects such as nintedanib on restrictive allograft syndrome should be assessed in further randomized double-blind placebo-controlled studies. © 2019 Société Française de Pharmacologie et de Thérapeutique.

Citation

Hélène Pluchart, Sébastien Chanoine, Amandine Briault, Johanna Claustre, Pierrick Bedouch. Restrictive allograft dysfunction after lung transplantation: is there a place for nintedanib?-a case report. Fundamental & clinical pharmacology. 2020 Jun;34(3):408-411